Hospital acquired infections
Patients admitted to or visiting hospitals can develop multiple infections, which are known as hospital-acquired infections (HAIs), or, simply, hospital infections. These conditions generally spread within nursing homes, dialysis centres, rehabilitation centres, outpatient surgery centres, and hospitals. Various bacterial, fungal, and viral pathogens can cause hospital infections. Intensive care units are also a common source of HAIs, which can be treated using antimicrobial drugs. Some therapeutic drugs available for these diseases are CAZ AVI, Surotomycin, MK-3415A, and Ceftolozane.
The growing susceptibility of the neonatal population to HAIs and the booming supply of drugs for these conditions is likely to lead to massive growth in the hospital infection therapeutics market in the coming years. Moreover, the lack of skilled nursing staff in healthcare settings, especially in emerging economies, is a key factor making therapeutic drugs more important. In many countries, these factors will offer pharmaceutical companies the opportunity to increase their production capacity in the coming years.
The number of hospitals is also rising worldwide, primarily due to government efforts to make healthcare more accessible. The World Bank reports the number of hospital beds per 1,000 people around the world increased to 2.894 in 2017 from 2.462 in 2005. A higher number of hospital beds means a larger number of hospital patients, which translates into a higher incidence of various HAIs. Ultimately, this will increase the demand for therapeutic drugs in the coming years.
North America has emerged as the hospital infection therapeutics market leader. The reason is the higher ratio of hospitals to the population of the region compared to other parts of the world. The surging population of ageing people in the continent and the increasing number of multi-drug-resistant microbial pathogens are also significant reasons leading to the rising demand for therapeutic drugs. APAC is also witnessing a rising demand for therapeutic drugs, especially in China and India, due to the growing prevalence of HAIs.
[edit] Related articles on Designing Buildings
Featured articles and news
Recharging Electrical Skills in Wales
Step by step collaborative solutions.
Ireland budget announcement 2025
CIOB responds with positivity, criticism and clarity.
The continued ISG fall out, where to go?
Support for ISG contractors, companies and employees.
New HES national centre for traditional building retrofit
Announced as HES publishes survey results which reveal strong support for retrofit.
Retrofit of Buildings, a CIOB Technical Publication
Expected to become one of the largest activities in the global construction industry.
Scope determination appeals and the Building Safety Act
Process explained following release of appeals guidance.
The ECA industry focus video channel
Keeping update with the industry session by session.
Over 25 recorded informations sessions freely available.
AT Awards 2024 ceremony East London October 25th.
Revisiting the AT community at the 2023 awards evening.
The Community Housing Fund and built affordable homes
CLTN reviews the impact of the Fund and calls for extension.
The grading system of the Regulator for Social Housing
A background, an explanation and ten recent enforcements.
Construction, repair and maintenance. Book review.
Putting new life into a city with a 1900 year history.
BSRIA Briefing 2024: Sustainable Futures speakers
Redefining Retrofit for Net Zero Living 22 Nov.
Wall of support for post-Grenfell regulation of electricians
Call for a shake-up of the construction industry highlighted on radio.
Digital sustainability through future AEC tools
Bringing together industry and academia to meet challenges.
Comments
[edit] To make a comment about this article, or to suggest changes, click 'Add a comment' above. Separate your comments from any existing comments by inserting a horizontal line.